Literature DB >> 19967149

Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.

Anetta Undas1, Przemyslaw Kaczmarek, Krzysztof Sladek, Ewa Stepien, Wojciech Skucha, Marcin Rzeszutko, Izabela Gorkiewicz-Kot, Wieslawa Tracz.   

Abstract

Increased risk of thrombotic events occurs in chronic obstructive pulmonary disease (COPD). Elevated fibrinogen and C-reactive protein (CRP), being common in COPD, are associated with formation of dense fibrin clots resistant to lysis. Statins have been found to display anti-inflammatory and antithrombotic effects. We investigated fibrin clot properties in COPD patients prior to and following statin therapy. Ex vivo plasma fibrin clot permeability, compaction, and fibrinolysis were assessed in 56 patients with stable COPD, aged 64.9 +/- 9.2 years (mean FEV(1), 54.7 +/- 15.9% predicted), versus 56 controls matched for age, sex and cardiovascular risk factors. Patients were then randomly assigned to receive simvastatin 40 mg/day (n = 28) or to remain without statins for three months (n = 28). Patients with COPD had lower clot permeability (6.1+/- 1.07 versus 9.2 +/- 0.9 10(-9) cm(2), p < 0.0001), decreased compaction (44.9 +/- 4.5 versus 63.9 +/- 6.1%, p < 0.0001), higher maximum D-dimer levels released from clots (4.23 +/- 0.55 versus 3.53 +/- 0.31 mg/l, p < 0.0001) with a decreased rate of this release (75.0 +/- 8.3 versus 80.9 +/- 8.0 microg/l/min, p = 0.03) and prolonged lysis time (9.84 +/- 1.33 versus 8.02 +/- 0.84 min, p < 0.0001) compared with controls. Scanning electron microscopy confirmed denser clot structure in COPD. Multiple linear regression analysis after adjustment for age and fibrinogen showed that in the COPD patients, CRP was the only independent predictor of permeability (R(2) = 0.47, p < 0.001) and lysis time (R(2) = 0.43, p < 0.001). Simvastatin improved clot properties (p < 0.05) despite unaltered CRP and irrespective of cholesterol reduction. Our study shows that fibrin clots in COPD patients are composed of much denser networks that are more resistant to lysis, and these properties can be improved by statin administration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19967149     DOI: 10.1160/TH09-02-0118

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  27 in total

1.  One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  María-Teresa García-Sanz; Juan-Carlos Cánive-Gómez; Laura Senín-Rial; Jorge Aboal-Viñas; Alejandra Barreiro-García; Eva López-Val; Francisco-Javier González-Barcala
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.

Authors:  Milosz Jankowski; Anetta Undas; Przemyslaw Kaczmarek; Saulius Butenas
Journal:  Thromb Res       Date:  2011-01-13       Impact factor: 3.944

3.  Validation study toward measuring the mechanical properties of blood clots using resonant acoustic spectroscopy with optical vibrometry.

Authors:  Gongting Wu; Alisa S Wolberg; Amy L Oldenburg
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2012-02-28

4.  Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition.

Authors:  Anetta Undas; Milosz Jankowski; Przemysław Kaczmarek; Krzysztof Sladek; Kathleen Brummel-Ziedins
Journal:  Thromb Res       Date:  2011-05-31       Impact factor: 3.944

Review 5.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

6.  The effects of sleep hypoxia on coagulant factors and hepatic inflammation in emphysematous rats.

Authors:  Jing Feng; Qing-shan Wang; Ambrose Chiang; Bao-yuan Chen
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

7.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

8.  Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice.

Authors:  Kellie R Machlus; Jessica C Cardenas; Frank C Church; Alisa S Wolberg
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

9.  Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

Authors:  Anant R C Patel; Beverly S Kowlessar; Gavin C Donaldson; Alex J Mackay; Richa Singh; Siobhan N George; Davinder S Garcha; Jadwiga A Wedzicha; John R Hurst
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

10.  Differential expression analysis for pathways.

Authors:  Winston A Haynes; Roger Higdon; Larissa Stanberry; Dwayne Collins; Eugene Kolker
Journal:  PLoS Comput Biol       Date:  2013-03-14       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.